A license agreement from UCB to Pheno Therapeutics will enable the acceleration of a promising new drug tackling neurological diseases towards clinical development.
In response to rising demand for inhalable treatments geard toward respiratory conditions, the company is adding capabilities and capacity at its Tampa site.
The synthetic biology company which specializes in producing ingredients for plant-inspired medicines has a pilot-scale manufacturing facility in the works.
A representative from the R&D tech provider offers advice on how to wrangle with a stressful, complicated process for better results and fewer headaches.
The group’s latest report glimpses inside the minds of pharma leaders, who are looking at a product’s full life-cycle development at the preclinical stage.
This year’s DIA Global Annual Meeting (taking place June 19-23 in Chicago) reunites professionals for face-to-face learning and networking opportunities.
An expert from the organization discusses ahead of his CPhI North America presentation how tomorrow’s drugs can’t all be formulated with yesterday’s excipients.
An expert from Pharmatech Associates offers a glimpse into the evolution of CM and previews a lively discussion during the upcoming CPhI North America event.
CPhI North America 2022 host city Philadelphia is set to become one of the world’s biggest cell and gene therapy manufacturing hubs. But it’s just one of many centers of innovation that are helping drive the US pharma and biopharma industry.
The CDMO has been awarded funding from the US government to work on treatments for sarin and other substances used frequently employed in chemical attacks.
An executive from Rephine Catena discusses how pharmaceutical companies dealing with supply chain challenges could draw lessons from the food industry.
Working with numerous partners, DiMe has introduced the 3Ps of Digital Endpoint Value to help inclusion of digital endpoints in drug reimbursement decisions.
A representative from the small-molecule solutions company explains how the ever-increasing mountain of life-sciences data has impacted drug development.
The expansion collates WuXi AppTec’s technology platform small molecule capabilities, including screening, discovery biology, pharmacology, and process R&D.
The contract services provider is now collecting and using peripheral blood mononuclear cells (PBMCs) for early phase clinical trials at its Antwerp, Belgium-based Clinical Pharmacology Unit (CPU).
Modeling and simulation can provide “meaningful prediction” of a drug’s pharmacodynamic range and maximum dose – the use of which might have prevented the tragic outcome of the BIAL 10-2474 trial in 2016, says Certara VP.
Ignoring pediatric considerations is no longer an option for the development of new medicines – though clinical trials in children are still not widely accepted by society, explains industry executive.
Lonza has increased its encapsulation capacity and invested in highly potent active pharmaceutical ingredient (HPAPI) services at a facility in Tampa, Florida.
PCI Pharma Services (PCI) has announced its intent to acquire Pharmaceutical Packaging Professionals (PPP) as the company focuses on growth and rapid expansion.
A patient-controlled injector and a prefilled pen for patients with hand dexterity issues were among the drug delivery technologies celebrated at PharmaPack Europe’s awards this year.
Nordic Universities will investigate 3D printing, electrospraying, and microfluidics in an industry supported collaboration aimed at revolutionising production in an age of personalised medicine.
The Danish competition authority has determined pharmaceutical distributor CD Pharma “abused its dominant position” by unfairly increasing prices for oxytocin-based Syntocinon.
The San Diego-CA-based contract research, development, and manufacturing organization (CDMO), BioDuro, has announced a cooperation agreement with Porton Pharma Solutions.
Metrion Biosciences has acquired a portfolio of more than 2,000 small molecule potassium channel inhibitors from Japan Tobacco Inc. (JT), with potential application in a variety of clinical indications.
Amneal Pharmaceuticals expects to bring production of some Impax Laboratories’ drugs in-house through a 100,000 sq. ft. expansion at its site in New York state.
XtalPi is advancing artificial intelligence models and prediction-driven research capabilities to improve drug design and small molecule development services.
Avista Pharma Solutions, Inc. has acquired Solid Form Solutions, Ltd. to provide customers with a broader suite of services as a single company, says CEO.
Rephine says its online Quality Assurance database transforms the lengthy active pharmaceutical ingredient (API) pre-selection process to just a couple of clicks.
PPD and Quotient Sciences have announced a new collaboration to accelerate pediatric drug development – as developing age-appropriate medicinal formulations will continue to be a focus of regulators, clinicians, and parents, says PPD senior VP.
LabCorp’s Covance has launched a new dedicated offering for biotech, medical device, and diagnostic companies following its purchase of Chiltern in 2017.
Investment firm LeBaronBrown Llc has acquired American International Chemical Inc (AIC), a distributor of ingredients for the pharmaceutical sector and other industries.